Join
today

Boliven PRO is more than just patent search

  • Build and save lists using the powerful Lists feature
  • Analyze and download your search results
  • Share patent search results with your clients

Patents »

US20090281328: PDK-1/AKT SIGNALING INHIBITORS

Share

Filing Information

Inventor(s) Ching-Shih Chen ·
Assignee(s) THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION ·
Correspondent CALFEE HALTER & GRISWOLD, LLP ·
Application Number US12476772
Filing date 06/02/2009
Publication date 11/12/2009
Predicted expiration date 10/04/2024
U.S. Classifications 548/254  · 548/377.1  ·
International Classifications C07D23112  · C07D40312  ·
Kind CodeA1
17 Claims, 2 Drawings


Abstract

A new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of formula I: wherein X is selected from the group consisting of alkyl and haloalkyl; Ar is an aryl radical selected from the group consisting of phenyl, biphenyl, naphthyl, anthryl, phenanthryl, and fluorenyl; and wherein Ar is optionally substituted with one or more radicals selected from the group consisting of halo, C1-C4 alkyl, C1-C4 haloalkyl, azido, C1-C4 azidoalkyl, aryl, alkylaryl, haloaryl, haloalkylaryl, and combinations thereof; and R is selected from the group consisting of nitrile, acetonitrile, ethylnitrile, propylnitrile, carboxamide, amidine, tetrazole, oxime, hydrazone, acetamidine, aminoacetamide, guanidine, and urea. Also provided are methods of using the compounds for the treatment and prevention of cancer in humans.

Independent Claims | See all claims (17)

  1. 1. A compound of formula I wherein X is selected from the group consisting of alkyl and haloalkyl; Ar is selected from the group consisting of phenyl, biphenyl, naphthyl, anthryl, phenanthrenyl, and fluorenyl; wherein Ar is optionally substituted with one or more substituents at any suitable position, R is selected from the group consisting of, —CH2CN, —CH2CH2CN, —CH2CH2CH2CN or metabolites or pharmaceutically acceptable salts thereof.
  2. 6. (canceled)
  3. 10. A compound of formula II X is selected from the group consisting of alkyl and haloalkyl; R is selected from the group consisting of —CN, —CH2CN, —CH2CH2CN, —CH2CH2CH2CN or metabolites or pharmaceutically acceptable salts thereof.
  4. 14. A compound of formula III: R is selected from the group consisting of —CN, —CH2CN, —CH2CH2CN, —CH2CH2CH2CN—CONH2 or metabolites or pharmaceutically acceptable salts thereof.
  5. 15-16. (canceled)
  6. 18-19. (canceled)

References Cited

The current document has no citations.

Referenced By

The current document is not referenced by other documents.

Patent Family

The current document is not in a family.